Celgene Corporation

April 2, 2018April 2, 2018

Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy

News

The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership between bluebird bio and Celgene. The companies ... Read more

February 23, 2018February 23, 2018

UT Southwestern Researcher Tells His CAR-T Therapy Story Ahead of Myeloma Trial

News

As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy, also known as CAR-T therapy, for multiple ... Read more

October 9, 2017

First Myeloma Patient in Study Treated with New CAR T-Cell Therapy bb21217

News

The first patient with relapsed/refractory multiple myeloma has been treated with the investigational therapy bb21217, according to the clinical-stage company bluebird bio. The treatment candidate bb21217, developed under a joint ... Read more

March 17, 2017

Myeloma UK Launches Reolysin Combo Trial for Relapsing Myeloma Patients

News

The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma patients. The MUK eleven Phase ... Read more

June 16, 2016June 16, 2016

Study Reveals Multiple Myeloma Treatment Disparities Between Caucasian, African-American Patients

News

Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple myeloma, revealing there are discrepancies in treatment ... Read more